Although the evidence is less clear for the G84E variant, the phenotypic impact of HOXB13 overexpression, the partially different oncogenic properties of the different mutations, the lack of truncating mutations, and the absence of loss of heterozygosity whenever tumors were tested [4,17], all concur with an oncogenic role of HOXB13 in prostate carcinogenesis. The gene discussed is HOXB13; the disease is medical procedure.